By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...

AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia drug in the ...

An unusual swelling in the legs and feet could indicate the onset of kidney damage. When the kidneys struggle to eliminate ...

The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

The following is a summary of “Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study,” published in the February 2025 issue of BMC Primary Care by ...

Global Anemia Treatment Market size is expected to be worth around USD 19.1 Billion by 2033, from USD 9.7 Billion in 2023, growing at a CAGR of 7.2% Lawrence John Prudour +91 91308 55334 ...